Revvity (Revvity) Debt-to-Equity

: 0.52 (As of Dec. 2023)

View and export this data going back to 1983. Start your Free Trial

Revvity's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $755 Mil. Revvity's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3,311 Mil. Revvity's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $7,873 Mil. Revvity's debt to equity for the quarter that ended in Dec. 2023 was 0.52.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Revvity's Debt-to-Equity or its related term are showing as below:

RVTY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.48 Med: 0.61 Max: 0.8
Current: 0.52

During the past 13 years, the highest Debt-to-Equity Ratio of Revvity was 0.80. The lowest was 0.48. And the median was 0.61.

RVTY's Debt-to-Equity is ranked worse than
65.99% of 197 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.24 vs RVTY: 0.52

Revvity Debt-to-Equity Historical Data

The historical data trend for Revvity's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revvity Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.80

0.59

0.72

0.62

0.52

Revvity Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																0.62	0.56	0.57	0.52	0.52

Competitive Comparison

For the Diagnostics & Research subindustry, Revvity's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Revvity Debt-to-Equity Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Revvity's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Revvity's Debt-to-Equity falls into.

Revvity Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Revvity's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(754.778	+	3310.517)	/	7872.739
	=	0.52

Revvity's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(754.778	+	3310.517)	/	7872.739
	=	0.52

Revvity (NYSE:RVTY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Revvity Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Revvity's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Revvity (Revvity) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Revvity Inc (NYSE:RVTY) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

PKN:Germany PKN:Germany

Address

940 Winter Street, Waltham, MA, USA, 02451

Website

https://www.revvity.com

Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.

Executives

Anita Gonzales	officer: Please See Remarks	940 WINTER STREET, REVVITY, WALTHAM MA 02451-1457
Andrew Okun	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Maxwell Krakowiak	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Daniel R Tereau	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Tajinder Vohra	officer: Please See Remarks	940 WINTER STREET, WALTHAM MA 02451-1457
Prahlad R. Singh	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 024511457
Joel S Goldberg	officer: See Remarks	940 WINTER STREET, WALTHAM MA 02451
Michelle Mcmurry-heath	director	C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703
James M Mock	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Sylvie Gregoire	director	940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Miriame Victor	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Peter Barrett	director	C/O ALNYLAM PHARMACEUTICALS, INC., 300 THIRD STREET, CAMBRIDGE MA 02142
Michel Vounatsos	director	BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Alexis P Michas	director	940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Pascale Witz	director	C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121